stockrowINmune Bio, Inc.
INMB Healthcare Biotechnology
INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024.
- Revenue
- +8.70%
- EPS
- +95.2%
- Free cash flow
- +55.4%
Quarter to June 2026, against a year earlier
Follow INMB
Alert me
INmune Bio, Inc. (INMB) EV/Sales
As of 6 November 2026, INmune Bio, Inc. (INMB) trades at a EV/Sales of 121×. Over the past ten years it has ranged from 0.0× (December 2021) to 1,506× (April 2024); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 139× | (76.41%) |
| FY2024 | 588× | (48.82%) |
| FY2023 | 1,150× | 419.07% |
| FY2022 | 221× | (59.23%) |
| FY2021 | 543× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | 1,194× | (18.30%) |
| Mar 2024 | 1,462× | 27.15% |
| Dec 2023 | 1,150× | 188.00% |
| Sep 2023 | 399× | (14.30%) |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PMN Promis Neurosciences compare | −5,573× |
| EYPT EyePoint, Inc. compare | −41.1× |
| IRLA IRulya Therapeutics Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | n/m |
| VERU Veru Inc. compare | 1.4× |
| PTHS Pelthos Therapeutics Inc. compare | 1.9× |
| INMB INmune Bio, Inc. | 121× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)